Physician profile
Jay Stuart Weinberg
NPI 1659321602
$2,208.65
in general payments reported to CMS, 2019-2025
29 companies · $426 in 2025
The $426 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $228 · 2021: $132 · 2022: $56.38 · 2023: $422 · 2024: $731 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,577.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $396.60 | 2021-2025 | Qelbree, Qelbree |
| Acadia Pharmaceuticals INC | $194.86 | 2023-2025 | Daybue |
| Corium, LLC | $169.22 | 2022-2025 | Azstarys |
| Abbott Laboratories | $161.79 | 2023 | Octrode |
| Amgen INC. | $150.00 | 2024 | Tavneos |
| Teva Pharmaceuticals USA, INC. | $127.02 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.42 | 2024 | |
| Ironshore Pharmaceuticals INC. | $109.04 | 2019-2024 | |
| Cranial Technologies, INC | $95.85 | 2019-2024 | Doc Band |
| Sanofi Pasteur INC. | $89.68 | 2019-2023 | |
| Pfizer INC. | $87.91 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.30 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $80.03 | 2019-2023 | Gardasil 9, M-M-R II, Vaqta |
| Collegium Pharmaceutical, INC. | $61.53 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $32.77 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $32.27 | 2024 | Voxzogo 1.2mg |
| Genentech USA, INC. | $28.39 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $21.78 | 2025 | Flumist Quadrivalent |
| Sanofi-Aventis U.S. LLC | $19.87 | 2025 | |
| Glaxosmithkline, LLC. | $17.85 | 2023 | Bexsero |
| Seqirus USA INC | $17.14 | 2021 | |
| Verrica Pharmaceuticals INC. | $17.03 | 2024 | Ycanth |
| Lnhc, INC | $16.91 | 2025 | Zelsuvmi |
| Ars Pharmaceuticals Operations, INC. | $16.20 | 2025 | Neffy |
| Mission Pharmacal Company | $15.49 | 2019 | |
| Tris Pharma INC | $15.13 | 2019 | |
| Shire North American Group INC | $14.56 | 2019 | |
| Alk-Abello, INC | $14.46 | 2023 | Ragwitek, Odactra, Grastek |
| Vertical Pharmaceuticals, LLC | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Weinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.